1. Home
  2. SCYX vs PFAI Comparison

SCYX vs PFAI Comparison

Compare SCYX & PFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • PFAI
  • Stock Information
  • Founded
  • SCYX 1999
  • PFAI 2015
  • Country
  • SCYX United States
  • PFAI Canada
  • Employees
  • SCYX N/A
  • PFAI N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • PFAI Farming/Seeds/Milling
  • Sector
  • SCYX Health Care
  • PFAI Consumer Staples
  • Exchange
  • SCYX Nasdaq
  • PFAI Nasdaq
  • Market Cap
  • SCYX 28.5M
  • PFAI 31.4M
  • IPO Year
  • SCYX 2014
  • PFAI 2025
  • Fundamental
  • Price
  • SCYX $0.71
  • PFAI $1.79
  • Analyst Decision
  • SCYX
  • PFAI
  • Analyst Count
  • SCYX 0
  • PFAI 0
  • Target Price
  • SCYX N/A
  • PFAI N/A
  • AVG Volume (30 Days)
  • SCYX 115.9K
  • PFAI 210.2K
  • Earning Date
  • SCYX 08-07-2025
  • PFAI 01-01-0001
  • Dividend Yield
  • SCYX N/A
  • PFAI N/A
  • EPS Growth
  • SCYX N/A
  • PFAI N/A
  • EPS
  • SCYX N/A
  • PFAI 0.07
  • Revenue
  • SCYX $2,630,000.00
  • PFAI $2,715,477.00
  • Revenue This Year
  • SCYX $463.61
  • PFAI N/A
  • Revenue Next Year
  • SCYX $310.80
  • PFAI N/A
  • P/E Ratio
  • SCYX N/A
  • PFAI $23.94
  • Revenue Growth
  • SCYX N/A
  • PFAI 1084.72
  • 52 Week Low
  • SCYX $0.66
  • PFAI $1.55
  • 52 Week High
  • SCYX $2.29
  • PFAI $4.40
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 39.58
  • PFAI N/A
  • Support Level
  • SCYX $0.70
  • PFAI N/A
  • Resistance Level
  • SCYX $0.75
  • PFAI N/A
  • Average True Range (ATR)
  • SCYX 0.05
  • PFAI 0.00
  • MACD
  • SCYX 0.00
  • PFAI 0.00
  • Stochastic Oscillator
  • SCYX 28.80
  • PFAI 0.00

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About PFAI Pinnacle Food Group Limited Class A Common Shares

Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups and are developing a hydroponic growing system for urban farms.

Share on Social Networks: